Global Rare Neurological Disease Treatment Market (2022 to 2027) – Growth, Trends, COVID-19 Impact and Forecasts – ResearchAndMarkets.com

Global Rare Neurological Disease Treatment Market (2022 to 2027) – Growth, Trends, COVID-19 Impact and Forecasts – ResearchAndMarkets.com




Global Rare Neurological Disease Treatment Market (2022 to 2027) – Growth, Trends, COVID-19 Impact and Forecasts – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Rare Neurological Disease Treatment Market – Growth, Trends, COVID-19 Impact, and Forecasts (2022 – 2027)” report has been added to ResearchAndMarkets.com’s offering.

The rare neurological disease treatment market is expected to register a CAGR of 8.6% during the forecast period.

Companies Mentioned

  • US WorldMeds LLC (Solstice Neurosciences LLC)
  • CSL Ltd
  • Merz Pharma GmbH & Co. KGaA
  • Aquestive Therapeutics Inc.
  • Kedrion Biopharma Inc.
  • Bayer AG
  • Pfizer Inc.
  • Novartis AG
  • Merck & Co. Inc. (EMD Serono Inc.)

Key Market Trends

The Small Molecules is Expected to Hold a Major Market Share in the Rare Neurological Disease Treatment Market

The small molecules segment holds a significant market share in the rare neurological disease treatment market. It is anticipated to show a similar trend over the forecast period due to the higher cost of biological drugs.

As per the report “Peer support for the Huntington’s community… by the Huntington’s community, Huntington’s Community Connect “, published in December 2020, in Australia, over 1,800 people have Huntington’s Disease, and approximately 9,000 individuals are at risk of developing the disease. Similarly, a very high concentration of Huntington’s Disease has been found in Venezuela, where the prevalence of Huntington’s Disease is about 700 per 100,000 population. According to the study published in ‘Science Direct’, titled ‘Biologics versus small molecules: Drug costs and patient access in 2021’ published in March 2021, the market for small molecules is rapidly expanding. Small molecules are increasingly being used to treat chronic disorders, and continue to dominate the pharmaceutical business, while being more impacted by policy implementation than biologics, which are still relatively new in healthcare. Therefore, rising adoption of small molecules in the treatment of chronic diseases like rare neurological disorders is expected to drive the growth of small molecule drug discovery market.

Moreover, the market segment growth is also contributed largely by collaboration among different market players for the research and discovery of small molecules for neurological diseases. For Instance, in July 2021, Servier and Nymirum, has entered into a strategic collaboration to identify and develop RNA-modulatory drugs for the treatment of neurological diseases. Under the collaboration agreement, Nymirum will leverage its proprietary DART Platform (Dynamic Atomic-Resolution RNA Targeting Platform) to discover novel small molecule therapeutics for multiple neurological targets.

Increasing incidences of rare neurological diseases worldwide, increasing focus on fast-track approvals, technological advancements, and growing awareness regarding early diagnosis of rare neurological diseases are the key driving factors of the small molecules segment.

North America is Expected to Hold a Significant Share in the Market in the Forecast Period

North America is expected to hold a major market share in the global rare neurological disease treatment market due to the availability of reimbursement, growing incidence of rare neurological diseases, and increasing research and development in this region. As per the data published by Center for Rare Neurological Disease Research Report in January 2021, the rare neurological diseases affect approximately 200,000 individuals in the United States.

Additionally, the launch of new treatments for treating these diseases such as huntington’s disease will drive the market. For instance, in December 2021, Novartis received approval from United States Food and Drug Administration (FDA) for Fast Track designation for branaplam (LMI070) for the treatment of Huntington’s disease (HD).

Key Topics Covered:

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Increasing Prevalence of Rare Neurological Diseases

4.2.2 Promising Pipeline Drugs for Treatment of Rare Neurological Diseases

4.2.3 Favorable Government Policies Worldwide for Speeding up Diagnostic Processes

4.3 Market Restraints

4.3.1 High Cost of Treatment

4.4 Porter’s Five Forces Analysis

5 MARKET SEGMENTATION (Market Size by Value – USD Million)

5.1 By Drug Type

5.1.1 Biologics

5.1.2 Small Molecules

5.2 By Mode of Administration

5.2.1 Injectables

5.2.2 Oral

5.2.3 Other Modes of Administration

5.3 Geography

5.3.1 North America

5.3.1.1 United States

5.3.1.2 Canada

5.3.1.3 Mexico

5.3.2 Europe

5.3.2.1 Germany

5.3.2.2 United Kingdom

5.3.2.3 France

5.3.2.4 Italy

5.3.2.5 Spain

5.3.2.6 Rest of Europe

5.3.3 Asia-Pacific

5.3.3.1 China

5.3.3.2 Japan

5.3.3.3 India

5.3.3.4 Australia

5.3.3.5 South Korea

5.3.3.6 Rest of Asia-Pacific

5.3.4 Middle-East and Africa

5.3.4.1 GCC

5.3.4.2 South Africa

5.3.4.3 Rest of Middle-East and Africa

5.3.5 South America

5.3.5.1 Brazil

5.3.5.2 Argentina

5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/pu30vu

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900